By vgreene, 28 October, 2021 KEY FINDINGS LPV regimens had little no effect on mortality vent initiation or length of stay
By vgreene, 28 October, 2021 Repurposed Antiviral Drugs for Covid 19 Interim WHO Solidarity Trial Results
By vgreene, 28 October, 2021 Study considerations randomized but open label unclear if adequate dose used limited number of intubated pts no collection of virological or laboratory parameters
By vgreene, 28 October, 2021 No significant difference in 28 day all cause mortality RR 1 03 95 CI 0 91 to 1 17 incl across subgroups no significant difference in time to discharge or proportion of pts discharged
By vgreene, 28 October, 2021 Hospitalized pts mean age 66 2y w suspected or confirmed COVID 19 randomized to LPV r 400 mg 100 mg bid plus SOC for up to 10 days n 1616 vs SOC only n 3424 25 pts w no ventilatory support most pts needed O2 only small proportion needed mech vent
By vgreene, 28 October, 2021 Randomized controlled open label adaptive platform study current analysis incl LPV r vs SOC only results for other tx arms published or forthcoming
By vgreene, 28 October, 2021 Study considerations randomized but open label unclear if adequate dose used limited number of intubated pts no collection of virological or laboratory parameters
By vgreene, 28 October, 2021 KEY FINDINGS compared w SOC LPV r did not lower 28 day mortality length of stay need for mech vent or risk of death
By vgreene, 28 October, 2021 Lopinavir Ritonavir in Patients Admitted to Hospital With COVID 19 RECOVERY A Randomised Controlled Open Label Platform Trial
